Harper Ellsworth Advertising, a Dallas-based agency, has been recognized as a finalist for the 2024 MM+M Awards in the category of 'Use of Hospital or Healthcare Services Marketing' for their work with Texas Radiotherapy. This nomination highlights the agency's dedication to excellence in healthcare marketing and its ability to effectively communicate complex health information to the public.
The MM+M Awards are renowned for celebrating creativity and effectiveness in healthcare marketing, with a rigorous selection process involving over 90 judges. The awards gala, set for October 10, 2024, in New York City, will honor industry leaders for their outstanding achievements. Kathlene Simmons, CEO of Harper Ellsworth, shared her excitement about the nomination, emphasizing the collaborative effort behind the campaign aimed at raising awareness about prostate cancer.
Melvin Strobbe, Project Creative Director, detailed the campaign's focus on profiling actual patients, a strategy rooted in patient truth, and praised the partnership with Texas Radiotherapy. This approach not only showcased creativity but also made a significant impact on engaging the target audience, underscoring the role of marketing in public health awareness.
The nomination reflects the competitive nature of the healthcare marketing industry and Harper Ellsworth's ability to meet its high standards. As a woman-owned business, the agency's success also highlights the growing diversity in the advertising industry. Their work with Texas Radiotherapy serves as a prime example of how effective marketing can contribute to better health outcomes by encouraging early detection and treatment.
For more details on the 2024 MM+M Awards, visit https://www.mmm-awards.com. To explore Harper Ellsworth's services, check out www.HarperEllsworthAdvertising.com.
